Immunaccel, LLC v. NextCure, Inc. – 1:21-cv-01755) – Statement on Pending Lawsuit
**CURRENT STATUS** – PARTIES HAVE AGREED TO A TEN (10) DAY STANDSTILL/STAY ON THE LAWSUIT**
Regarding the pending lawsuit described in NXTC’s SEC filings under Legal Proceedings as shown below:
On December 14, 2021, a purported misappropriation of certain trade secrets lawsuit was filed in Federal District Court for the District of Delaware, styled Immunaccel, LLC v. NextCure, Inc., Case No. 1:21-cv-01755-UNA (the “Immunaccel action”). The lawsuit alleges that the Company misappropriated certain trade secrets belonging to Immunaccel related to a drug discovery and screening platform named IMMUNE 3D. The complaint alleged two causes of action, one under the Delaware Uniform Trade Secrets Act and another under the Federal Defend Trade Secrets Act. The Company filed a motion to dismiss the complaint on April 22, 2022. In response to the Company’s motion to dismiss, Immunaccel filed an amended complaint on June 21, 2022 (“Amended Complaint”). The Amended Complaint added as parties to the Immunaccel action Screen Therapeutics LLC (“Screen”), an affiliate entity of Immunaccel, and Company’s CEO Michael Richman in his capacity as an individual. The Amended Complaint alleges that Mr. Richman breached certain contractual and fiduciary duties owed to Screen due to Mr. Richman’s prior relationship as an investor in, and purported advisor to, Screen.
-
The lawsuit is currently at the Motion to Dismiss (MTD) phase and parties have agreed to a temporary stay/standstill. We are not accepting unsolicited inquiries and/or commenting on the case at this time. We encourage you to visit our dedicated website to the lawsuit to read the complaints at Screen-Immunaccel Lawsuit.
-
Mr. Richman is a member/unit holder of Screen Therapeutics LLC since 2013.
-
Interested Parties may contact us at: info@screenimmunaccel-legal.com
———————————————————————————————————————
***NEXTCURE’S SEC STATEMENTS AND FILINGS***
We appreciate the inquiries regarding Mr. Richman’s role with Screen Therapeutics LLC and that relate to his SEC disclosures. Inquiries that are unrelated to our pending lawsuit and their associated claims should be directed to the following contacts at NextCure:
- Mr. Kevin Shaw – NextCure’s SVP of Legal Affairs
- NextCure’s Investor Relations